Studies have shown that in patients with pancreatic cancers with 2 or more FDR with pancreatic cancer, the prevalence of BRCA2 mutations ranges from 17% to 19% [20,21]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.